Island Pharmaceuticals Secures $3.6 Million for Clinical Advancements

Island Pharmaceuticals Ltd ( (AU:ILA) ) has shared an announcement.

Island Pharmaceuticals Ltd has announced a successful $3.6 million capital raise through the placement of 24 million new shares at $0.15 each. The funds will be used to advance the clinical development of ISLA-101, particularly for a larger Phase 2 trial in dengue fever, and to explore new asset expansion opportunities. This strategic funding comes at a crucial time as the company awaits results from its Phase 2a/b PROTECT trial, which will guide the future development of ISLA-101. The placement saw strong interest from existing and new investors, including company directors, and provides financial flexibility for pursuing clinical trials for new molecules.

More about Island Pharmaceuticals Ltd

Island Pharmaceuticals Ltd is an Australian antiviral drug development company focused on creating treatments for viral infections. The company is actively involved in the clinical development of its lead asset, ISLA-101, and is exploring opportunities for expanding its asset portfolio, particularly in international markets where diseases like dengue fever are prevalent.

Average Trading Volume: 151,762

Technical Sentiment Signal: Buy

Current Market Cap: A$37.85M

Learn more about ILA stock on TipRanks’ Stock Analysis page.